NEW YORK, July 14, 2026, 04:31 (EDT)
Agenus Inc. NASDAQ:AGEN shares closed 82.7% higher at $6.12 on Monday after the cancer-drug developer unveiled financing of up to $340 million for a pivotal colon-cancer study. The stock reached $8.70 and roughly 174 million shares changed hands. The regular U.S. session had not opened at the dateline; Nasdaq was scheduled to trade normally on Tuesday.
The rally has a catch. Only $85 million is due at closing; the remaining $255 million — three-quarters of the headline amount — arrives only if investors exercise warrants. A warrant gives an investor the right, but not the duty, to buy shares at a fixed price.
The deal therefore works like staged clinical financing, not a blank check. Series A warrants expire shortly after Agenus discloses that 60 ROBBIN patients have been dosed, while Series B warrants have a similar short window after pathology data from at least 50 patients. Commodore Capital may appoint two directors while it owns at least 5%, and the filing bars the proceeds from funding buybacks, business-development deals or voluntary early debt repayment.
| Funding layer | Gross cash | Common-share equivalents | Purchase or exercise price | Clinical clock |
|---|---|---|---|---|
| Closing package | About $85 million | 23.04 million | $3.69 package price | Expected to close July 15 |
| Series A warrants | Up to about $85 million | 21.14 million | $4.02 | 30 days after disclosure that 60 patients have been dosed, or five years |
| Series B warrants | Up to about $170 million | 33.80 million | $5.03 | 30 days after pathology data on at least 50 patients; also linked to Series A expiry, or five years |
| Total | Up to about $340 million | 77.98 million | — | Full warrant exercise required for the headline total |
Amounts are rounded. Agenus said the upfront-only path would fund operations into the third quarter of 2027; full exercise would extend its runway through 2031.
The structure can fund the trial, but it would also rewrite the capitalization table. Against Agenus’ last official count of 41.64 million shares on May 7, the 77.98 million new common-share equivalents amount to 187.3% of the base. Full conversion would take the illustrative count to 119.62 million, leaving the pre-deal common-stock base representing about 34.8% of the enlarged total.
| Illustrative scenario | Common shares or equivalents | Pre-deal base as share of total |
|---|---|---|
| May 7 official count | 41.64 million | 100.0% |
| After closing package | 64.68 million | 64.4% |
| After both warrant series | 119.62 million | 34.8% |
The calculation assumes all closing securities and both warrant series become common shares. It excludes older warrants, stock options and any stock sales after May 7, so the eventual percentage could differ.
The first $85 million still changes near-term liquidity. Agenus had $35 million in cash at March 31 and raised another $11.7 million net after quarter-end through an at-the-market program, which sells shares gradually into public trading. The upfront gross amount is about 2.4 times the quarter-end cash balance; first-quarter cash payments were $51.8 million, though Agenus said a large portion reflected the Zydus transaction and clinical-supply obligations rather than recurring spending.
ROBBIN is planned to enroll 850 previously untreated high-risk Stage II or Stage III MSS patients, split evenly between BOT+BAL before surgery plus standard care and standard care alone. MSS, or microsatellite stable, describes tumors without the DNA-repair defect that often makes immunotherapy work; neoadjuvant means treatment before surgery, while event-free survival, or EFS, measures time before recurrence, progression or death. First dosing is targeted for the first quarter of 2027, pathology results for the second half of 2027, interim EFS for late 2029 and final EFS for late 2030; Chief Medical Officer Steven O’Day said MSS disease “has resisted standard checkpoint inhibitors.” Agenus Inc.
The case for starting that trial rests on early pathology, not randomized survival evidence. On Monday’s investor call, City of Hope investigator Pashtoon Kasi said about 59% of NEST’s MSS patients had at least 50% tumor regression, 41% had at least 90%, and roughly one-third had no viable tumor at surgery. He said follow-up “is a little early”; Netherlands Cancer Institute investigator Myriam Chalabi added that the small patient group “has to be kept in mind.” StockAnalysis
The pivot also ends a study that had barely started. BATTMAN, an 830-patient Phase 3 trial in late-line, unresectable metastatic MSS colorectal cancer, began enrollment in April and is being dropped after about three months. It tested the same BOT+BAL combination across Canada, France, Australia and New Zealand; Agenus said it would honor obligations to patients already receiving treatment.
Approved checkpoint competition sits in different biology. Merck & Co. NYSE:MRK has first-line approval for Keytruda, while Bristol Myers Squibb NYSE:BMY has approval for Opdivo plus Yervoy, in unresectable or metastatic MSI-H/dMMR colorectal cancer — tumors with faulty DNA mismatch repair. Those approvals do not cover the curative-intent, earlier-stage MSS population targeted by ROBBIN.
But the financing and the science could weaken together. The published 2025 NEST meeting update covered just 24 patients, including four with dMMR disease, and deep tumor clearance in surgical tissue is not proof of longer EFS in an 850-patient randomized study. Slow enrollment, immune toxicity or weak 2027 pathology data could deter warrant exercise; if holders decline to pay $4.02 or $5.03, much of the $255 million will not arrive, while investors must still price an equity overhang that can almost triple the May share count. Monday’s rally priced more than the first check. The 2027 milestones must earn the rest.
